Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Vomiting 31Nausea 27Neoplasms 14Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 7Multiple Myeloma 6Breast Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Burkitt Lymphoma 5Sezary Syndrome 4Primary Myelofibrosis 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myeloproliferative Disorders 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Hairy Cell 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic Syndromes 3Lymphoma, Large-Cell, Anaplastic 3

Interventions

Ondansetron 1Injections 1Dexamethasone 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pediatric Solid Tumor, Unspecified, Protocol Specific × Ondansetron × Clear all
NCT06208917 2024-01-17

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Sun Yat-sen University

Phase 3 Recruiting
376 enrolled
Other solid neoplasm

Pediatric Solid Tumor, Unspecified, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡